StreetInsider.com News Articles

Firefly announces brain wave biomarkers for ADHD subtype diagnosis

Fri, 13 Mar 2026 07:56:22 -0400

Firefly Neuroscience (NASDAQ: AIFF) announced research advancement using its FDA-cleared Evoke System to potentially distinguish between three main subtypes of attention-deficit/hyperactivity disorder through EEG brain scans.

The company stated its AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has among hyperactive and impulsive, inattentive, and combined types. Current ADHD diagnosis relies on symptom-based criteria without objective biological tools for subtype differentiation, according to the company.

ADHD affects over 22 million Americans and represents a U.S. treatment market estimated at over $10 billion. Healthcare professionals currently use the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) to distinguish between ADHD

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Fri, 13 Mar 2026 07:55:00 -0400

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive¹

Firefly’s AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has — potentially complementing subjective symptom checklists with neural signal-based precision

Subtype identification could change the clinical equation: Firefly’s platform may help clinicians determine the most appropriate treatment type, inform dosage decisions, and potentially monitor whether an intervention is working

The breakthrough advances Firefly’s mission to build the world’s first EEG/ERP brain foundation

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Fri, 13 Mar 2026 07:55:00 -0400

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive¹

Firefly’s AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has — potentially complementing subjective symptom checklists with neural signal-based precision

Subtype identification could change the clinical equation: Firefly’s platform may help clinicians determine the most appropriate treatment type, inform dosage decisions, and potentially monitor whether an intervention is working

The breakthrough advances Firefly’s mission to build the world’s first EEG/ERP brain foundation

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Fri, 13 Mar 2026 07:55:00 -0400

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive¹

Firefly’s AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has — potentially complementing subjective symptom checklists with neural signal-based precision

Subtype identification could change the clinical equation: Firefly’s platform may help clinicians determine the most appropriate treatment type, inform dosage decisions, and potentially monitor whether an intervention is working

The breakthrough advances Firefly’s mission to build the world’s first EEG/ERP brain foundation

Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD

Fri, 13 Mar 2026 07:55:00 -0400

Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date, remained elusive¹

Firefly’s AI-powered EEG/ERP technology may help identify which ADHD subtype a patient has — potentially complementing subjective symptom checklists with neural signal-based precision

Subtype identification could change the clinical equation: Firefly’s platform may help clinicians determine the most appropriate treatment type, inform dosage decisions, and potentially monitor whether an intervention is working

The breakthrough advances Firefly’s mission to build the world’s first EEG/ERP brain foundation

Form 8-K FIREFLY NEUROSCIENCE, For: Mar 12

Thu, 12 Mar 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260312/26153769.html

Form 8-K FIREFLY NEUROSCIENCE, For: Mar 12

Thu, 12 Mar 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260312/26153769.html

Form 4 FIREFLY NEUROSCIENCE, For: Mar 10 Filed by: Lipschitz Gregory

Thu, 12 Mar 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260312/26153729.html

Form 4 FIREFLY NEUROSCIENCE, For: Mar 10 Filed by: Lipschitz Gregory

Thu, 12 Mar 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260312/26153729.html

Form 4 FIREFLY NEUROSCIENCE, For: Mar 10 Filed by: DeCaprio David

Thu, 12 Mar 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260312/26153740.html

Form 4 FIREFLY NEUROSCIENCE, For: Mar 10 Filed by: DeCaprio David

Thu, 12 Mar 2026 16:30:00 -0400
si-local-file:///var/storage/secattach/20260312/26153740.html

Firefly Neuroscience expands commercial footprint by 20-fold in 2025

Wed, 04 Mar 2026 07:45:10 -0400

Firefly Neuroscience Inc. (NASDAQ: AIFF) reported a 20-fold expansion of its commercial footprint and a 33-fold increase in EEG/ERP brain scan volumes for 2025, according to a company statement.

The AI company ended 2025 with partnerships involving 99 commercial users who completed more than 10,800 EEG/ERP brain scans. The increases represent year-over-year growth of 1,880% in partner sites and 3,227% in EEG/ERP clinical assessments since the end of 2024.

The growth follows Firefly's acquisition of Evoke Neuroscience Inc. and execution of internal growth initiatives. The company stated it is using NVIDIA L40S GPU acceleration to power EEG/ERP processing as it works toward

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

Wed, 04 Mar 2026 07:45:00 -0400

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -

- Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain -

KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

Wed, 04 Mar 2026 07:45:00 -0400

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -

- Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain -

KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

Wed, 04 Mar 2026 07:45:00 -0400

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -

- Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain -

KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold

Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration

Wed, 04 Mar 2026 07:45:00 -0400

- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -

- Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain -

KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold

Form 8-K FIREFLY NEUROSCIENCE, For: Feb 03

Wed, 04 Feb 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260204/25947248.html

Form 8-K FIREFLY NEUROSCIENCE, For: Feb 03

Wed, 04 Feb 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260204/25947248.html

Form 424B5 FIREFLY NEUROSCIENCE,

Tue, 03 Feb 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260203/25939841.html

Form 424B5 FIREFLY NEUROSCIENCE,

Tue, 03 Feb 2026 16:45:00 -0400
si-local-file:///var/storage/secattach/20260203/25939841.html

Form SCHEDULE 13D/A FIREFLY NEUROSCIENCE, Filed by: Windsor Private Capital LP

Fri, 30 Jan 2026 19:53:00 -0400
si-local-file:///var/storage/secattach/20260130/25924976.html

Form SCHEDULE 13D/A FIREFLY NEUROSCIENCE, Filed by: Windsor Private Capital LP

Fri, 30 Jan 2026 19:53:00 -0400
si-local-file:///var/storage/secattach/20260130/25924976.html

Form SCHEDULE 13D/A FIREFLY NEUROSCIENCE, Filed by: Windsor Private Capital LP

Fri, 30 Jan 2026 19:53:00 -0400
si-local-file:///var/storage/secattach/20260130/25924977.html

Form SCHEDULE 13D/A FIREFLY NEUROSCIENCE, Filed by: Windsor Private Capital LP

Fri, 30 Jan 2026 19:53:00 -0400
si-local-file:///var/storage/secattach/20260130/25924977.html

Form SCHEDULE 13D/A FIREFLY NEUROSCIENCE, Filed by: Windsor Private Capital LP

Wed, 31 Dec 2025 19:21:00 -0400
si-local-file:///var/storage/secattach/20251231/25795159.html